Clinical trials: Anger
Hepatitis C
EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients
This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV) and in treatment-naive subjects with GT1/3…
- Trial name
- NCT02652377
- Testing
- EDP-494
- Where
- New Zealand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Alzheimer's Disease, Healthy Non-elderly and Elderly Adults
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
This is a Phase 1/2a, multi-center, placebo-controlled, double-blinded, randomized, multiple ascending dose (MAD) clinical trial to determine the safety and maximum tolerated dose of AL001.
- Trial name
- "MAD" (NCT05363293)
- Testing
- AL001
- Where
- 2 sites in United States, Canada
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Alzamend Neuro, Inc.
Healthy
Single Ascending Dose and Multiple Ascending Dose Study of Niclosamide Inhalation Powder in Healthy Adult Subjects
This is a Phase 1 (healthy adult volunteers), 2-part, double-blind, randomized, placebo controlled trial to evaluate the safety and pharmacokinetic (PK) profiles of escalating single doses of Niclosamide Inhalation Powder versus…
- Trial name
- NCT05168644
- Testing
- Niclosamide Inhalation Powder
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- TFF Pharmaceuticals, Inc.
Pain
Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)
This is a two-part randomized, double-blind, placebo-controlled study.
- Trial name
- NCT05484414
- Testing
- SRP-3D (diethylamide)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- South Rampart Pharma, Inc.
Borderline Personality Disorder
Treatment of Aggression, Anger and Emotional Dysregulation in Borderline Personality Disorder
This study examines the effects of 12 months of dialectical behavior therapy (DBT) for subjects with borderline personality disorder on aggression, anger and emotional dysregulation.
- Trial name
- NCT00467038
- Testing
- Dialectical Behavior
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Major Depressive Disorder
A Study of HS-10353 in Chinese Participants.
The primary objective of this study is to assess the safety and tolerability of single and multiple oral administered doses of HS-10353 separately in Chinese healthy and major depressive disorder subjects.
- Trial name
- NCT05195203
- Testing
- HS-10353
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Healthy Adult Participants
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
ARN-75039 is proposed for the treatment of subjects with LASV infection, Lassa hemorrhagic fever, a potentially fatal human disease associated with Lassa viruses, with the most significant unmet medical need.
- Trial name
- NCT05735249
- Testing
- ARN-75039 oral capsules
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Arisan Therapeutics, Inc.
Duchenne Muscular Dystrophy
First in Human SAD/MAD Safety and PK Study With Adult DMD Safety and PK Cohort
This is a first-in-human (FIH), Phase 1 study of orally administered SAT-3247 in healthy adult volunteers (HVs) and adult participants with DMD to determine safety, tolerability, pharmacokinetics and pharmacodynamics.
- Trial name
- NCT06565208
- Testing
- SAT-3247
- Where
- 2 sites in Australia
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Satellos Bioscience, Inc.
Asperger's Disorder, Asperger Disorder
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum SI/SGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.
Safety Issues, Tolerance
Phase 1 SAD/MAD Study of CVN766 in Healthy Volunteers
Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Doses of CVN766 in Healthy participants.
- Trial name
- NCT05105243
- Testing
- CVN766
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Cerevance
Forgiveness
Proposing Forgiveness Therapy Within Prison
Previous studies found that a large number of prisoners experienced unjust treatment from others, which can lead to deep inner pain or anger, prior to criminal perpetration.
- Trial name
- NCT04373954
- Testing
- Forgiveness Therapy, Carey Guides
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthy, Osteoarthritis
Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation
This is a first in human, randomized, double-blind, placebo-controlled SAD (with food effect) followed by a MAD study of Trichomylin® conducted in healthy adult participants.
- Trial name
- HOPE (NCT04867057)
- Testing
- Trichomylin for SAD, Trichomylin for MAD
- Where
- Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- ZYUS Life Sciences Inc.
Depression, Somatization Disorder
Effects of Emotional Stimulation on the Stress Levels of Healthy Persons
The purpose of this study is to evaluate the effects of a short-term emotional stimulation on the mood of healthy persons.
- Conditions
- Depression, Somatization Disorder, Anger, Anxiety
- Trial name
- NCT01187797
- Testing
- Emotional stimulation
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Normal Healthy Subjects
Study to Evaluate HT-4253 in Healthy Subjects
The primary objectives of this study are to evaluate the safety and tolerability of HT-4253 when administered as single oral doses and multiple oral doses at escalating dose levels in healthy volunteer subjects.
- Trial name
- NCT06537817
- Testing
- HT-4253
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Halia Therapeutics, Inc.
Healthy
AZD7325 Japan Multiple Ascending Dose (MAD) Study
The purpose of this study is to evaluate the safety and tolerability after repeated ascending doses of AZD7325 in Japanese healthy male subjects.
- Trial name
- JMAD (NCT00945425)
- Testing
- AZD7325
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis
Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064
This is a 6-part first-in-human study in up to approximately 184 participants. Parts 1 to 5 is in health volunteers and part 6 is in subjects with atopic dermatitis.
- Trial name
- NCT03918980
- Testing
- LOU064
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Hyperuricemia
A Safety and Tolerability Study of FCN-207 in Healthy Volunteers
This research study is studying an investigational drug called FCN-207 in healthy adult males or females.
- Trial name
- NCT04622124
- Testing
- fasted vs. high-fat meal
- Where
- China
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Fochon Pharmaceuticals, Ltd.
Fibrosis, Inflammation
A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of RXC007.
- Conditions
- Fibrosis, Inflammation, Idiopathic Pulmonary Fibrosis, Non-alcoholic Steatohepatitis
- Trial name
- NCT04931147
- Testing
- RXC007
- Where
- United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Redx Pharma Ltd
Inflammatory Bowel Disease, Colitis, Ulcerative
LMT503 First-in-human SAD, MAD, and FE Study
This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and…
- Conditions
- Inflammatory Bowel Disease, Colitis, Ulcerative, Crohn Disease
- Trial name
- NCT05659953
- Testing
- LMT503
- Where
- Netherlands
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lmito Therapeutics Inc.
Major Depressive Disorder, Healthy Volunteer
First-In-Human (FIH), Single Ascending Dose (SAD) Study and Multiple Ascending Dose (MAD) Study of SP-101 Injection
The goal of this First-In-Human (FIH) trial is to learn about safety, tolerability and pharmacokinetics of single and multiple ascending doses of SP-101 in healthy adult volunteers.
- Trial name
- NCT07334249
- Testing
- SP-101 injection
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Synphatec (Shanghai) Biopharmaceutical Technology Co., Ltd.